Table 3.
Gender differences in DM-HT groups. ICU (intensive care unit), CT (computerized tomography), high-flow nasal cannula (HFNC).
| Male (n. 286) | Female (n. 270) | p Value | |
|---|---|---|---|
| Epidemiological Link | |||
| Community | 180 (66.7%) | 87 (32.5%) | <0.0001 |
| Nosocomial | 79 (27.8%) | 70 (25.9%) | 0.0016 |
| RSA | 116 (40.7%) | 20 (7.4%) | <0.0001 |
| Symptoms | |||
| Fever | 120 (42.0%) | 230 (85.2%) | <0.0001 |
| Dyspnea | 148 (51.9%) | 40 (14.8%) | <0.0001 |
| Rx lung | |||
| Atypical | 242 (84.8%) | 69 (25.7%) | <0.0001 |
| Typical | 44 (15.2%) | 200 (74.3%) | <0.0001 |
| CT lung | |||
| Atypical | 286 (100.0%) | 240 (88.9%) | <0.0001 |
| Typical | 0 (0.0%) | 30 (11.1%) | <0.0001 |
| PF ratio < 300 (%) | 58 (20.3%) | 40 (14.8%) | <0.0001 |
| Discharge at home (%) | 9 (3.14%) | 206 (76.5%) | <0.0001 |
| ICU admission (%) | 191 (66.9%) | 34 (12.8%) | <0.0001 |
| Death rate (%) | 49 (17.3%) | 28 (10.7%) | <0.0001 |
| O2 therapy | 140 (51.8%) | 83 (29.1%) | <0.0001 |
| HFNC | 270 (100.0%) | 267 (93.7%) | <0.0001 |
| Hydroxychloroquine | 128 (44.9%) | 260 (96.3%) | <0.0001 |
| Darunavir/ritonavir | 21 (7.4%) | 0 (0.0%) | Ns |
| LMWH therapy | 201 (70.4%) | 82 (30.5%) | <0.0001 |